Comparative Pharmacology
Head-to-head clinical analysis: CARMOL HC versus DERMABET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARMOL HC versus DERMABET.
CARMOL HC vs DERMABET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carmol HC is a combination of urea (a keratolytic) and hydrocortisone (a corticosteroid). Urea softens and dissolves the intercellular matrix of the stratum corneum, promoting desquamation and enhancing penetration of hydrocortisone. Hydrocortisone suppresses inflammation by induction of phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Betamethasone dipropionate is a corticosteroid that diffuses across cell membranes and binds to glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. It induces phospholipase A2 inhibitory proteins (lipocortins), thereby inhibiting the release of arachidonic acid and decreasing the synthesis of prostaglandins and leukotrienes. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects.
Apply a thin film to affected area twice daily; topical, not for ophthalmic or oral use.
Apply a thin layer to affected area once or twice daily. Maximum 50 g per week.
None Documented
None Documented
1-2 hours (hydrocortisone acetate); clinical effects persist longer due to local anti-inflammatory action; tissue half-life not well defined.
Terminal elimination half-life: 3-4 hours; prolonged in hepatic impairment
Primarily renal excretion of metabolites (40-60%) as glucuronide and sulfate conjugates; <10% unchanged; biliary/fecal elimination accounts for <20%.
Renal (60-70% as unchanged drug and metabolites), biliary/fecal (30-40%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid